CompletedPhase 2NCT02452554
Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Studying DICER1 tumor-predisposition syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- James I GellerChildren's Oncology Group
- Intervention
- Laboratory Biomarker Analysis(other)
- Enrollment
- 62 enrolled
- Eligibility
- 30 years · All sexes
- Timeline
- 2015 – 2021
Study locations (30)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Kaiser Permanente Downey Medical Center, Downey, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Children's Hospital and Research Center at Oakland, Oakland, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- Rady Children's Hospital - San Diego, San Diego, California, United States
- UCSF Medical Center-Mission Bay, San Francisco, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Yale University, New Haven, Connecticut, United States
- Alfred I duPont Hospital for Children, Wilmington, Delaware, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02452554 on ClinicalTrials.govOther trials for DICER1 tumor-predisposition syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06647953Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary BlastomaChildren's Oncology Group
- RECRUITINGNCT01247597DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History StudyNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNANCT01464606International Pleuropulmonary Blastoma (PPB) Treatment and Biology RegistryChildren's Hospitals and Clinics of Minnesota